NeuroVive to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

Lund, Sweden, September 7, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm:
NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the
company is scheduled to present at the Rodman & Renshaw 18th Annual Global
Investment Conference held September 11-13, 2016 in New York, US. During the
presentation, an update regarding NeuroVive's research and development programs
will be provided.
The presentation will include the clinical phase II projects related to acute
kidney injury (AKI) prevention and treatment of traumatic brain injury (TBI).
Also, the pre-clinical project NVP015 targeting genetic mitochondrial disorders
will be presented (recently presented in Nature
Communications (http://www.nature.com/ncomms/2016/160809/ncomms12317/full/ncomms
1 
2317.html)).

The presentation will take place on September 13, at 5:05 p.m. EDT /11:05 p.m.
CEST. The audio and slide presentation will be webcasted live and can be
accessed via the NeuroVive web site. To access the live and replay presentations
please go to http://www.neurovive.com/en/investor/company-presentations/ .

About NeuroVive

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) is a pioneer
in mitochondrial medicine and a company committed to the discovery and
development of highly targeted candidates that preserve mitochondrial integrity
and function in areas of significant therapeutic need. NeuroVive's business
approach is driven by value-adding partnerships with mitochondrial research
institutions and commercial partners across the globe.

NeuroVive's portfolio consists of two clinical projects, one in acute kidney
injury (CicloMulsion®) and one in traumatic brain injury (NeuroSTAT®). The
candidate drug NeuroSTAT has orphan drug designation in Europe and in the US for
treatment of moderate to severe traumatic brain injury and is currently being
evaluated in the CHIC study. CicloMulsion is being evaluated in an on-going
study, CiPRICS, in acute kidney injury during major surgery. Furthermore, the
R&D portfolio consists of two late stage discovery programs and one compound in
preclinical development.

NeuroVive is listed on Nasdaq Stockholm, Sweden, Small Cap, under the ticker
symbol NVP. The share is also traded on the OTC Markets Group Inc market in the
US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market.

For investor relations and media questions, please contact:
Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
www.neurovive.com

This information is information that NeuroVive Pharmaceutical AB (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the contact
person set out above, at 02:00 p.m. CEST on Sep 7, 2016.